Navigation Links
Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
Date:4/24/2013

LAVAL, Quebec, April 24, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that it has received approval by the Antimonopoly Committee of Ukraine (the "AMC") of its proposed acquisition of Obagi Medical Products, Inc. (NASDAQ: OMPI) ("Obagi") pursuant to a tender offer and subsequent merger. The receipt of the AMC's approval of the acquisition satisfies one of the conditions to consummate the tender offer.  As previously announced, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired.  The consummation of the tender offer remains subject to other customary conditions, all of which the parties expect to be satisfied.

The tender offer for all of the outstanding shares of common stock of Obagi at a price of $24.00 per share, net to the seller in cash, without interest (less any required withholding taxes) expires at 12:00 midnight, New York City time, on Thursday, April 25, 2013 (which is one minute after 11:59 p.m. New York City time on Wednesday, April 24, 2013).  Valeant does not expect to further extend the offer and expects to complete the acquisition of Obagi on April 25, 2013 or shortly thereafter.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Fo
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
2. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
3. Valeant Pharmaceuticals Provides Update to Recent Event
4. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
5. Valeant Pharmaceuticals Announces Private Exchange Offer
6. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
7. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
8. Valeant Completes Acquisition Of Natur Produkt In Russia
9. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
10. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
11. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
(Date:7/27/2015)... ... 27, 2015 , ... BESLER Consulting today announced the publication ... for Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP ... as the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights ...
(Date:7/27/2015)... ... July 27, 2015 , ... Gary D. Breslow, MD, FACS, is ... Founder and Medical Director of The Breslow Center in Paramus, NJ, which offers the ... in Northern New Jersey. The Breslow Center also hosts a world-class medical spa ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... For a ... summer promotion on Zoom teeth whitening. Summer is a great time to change up ... different reasons, but discolored teeth can really affect your self-esteem. Over time, the enamel ...
(Date:7/27/2015)... , ... July 27, 2015 , ... According to an ... rate of hepatitis C has increased in Tennessee stemming from intravenous drug use. Intravenous ... medical professionals at risk for contracting communicable diseases including Hepatitis B and C and ...
Breaking Medicine News(10 mins):Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Doc, Dr. Gary Breslow, has launched Zwivel; a New Online Cosmetic Consultation Service for Doctors and Patients 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3
... CLARA, Calif., Dec. 15 Today, Coastal Healthcare Administrators ... the first time since its inception in 1961. ... and provider contracts previously held by the Physicians Foundation ... based healthcare philosophy, Coastal maintains close working relationships with ...
... prostate cancer are often treated with hormones, but when ... different blood vessels, reveals a thesis from the Sahlgrenska ... paves the way for new treatments for hormone-resistant prostate ... when the prostate cancer has spread, most patients are ...
... London, ON A new study published by The University ... for paid and unpaid work report higher average measures of ... The ,shared roles, category, where each partner,s unpaid work ... is a growing category that now represents more than 25 ...
... Although seen as a potential heart disease therapy, ... of a transfer protein may not be effective, a ... Human Nutrition Research Center on Aging (USDA HNRCA) at ... found an association between low plasma cholesterol ester transfer ...
... ... the secretive Central Intelligence Agency has requested documents from an investigative journalist, even though ... Information Act. , ... Walterville (Vocus) December 15, 2009 -- In a bizarre about-face, the secretive Central Intelligence ...
... ... and Large Volume Injections Dangerous , ... New York, NY (Vocus) December 15, 2009 -- The popularity and ... RealSelf.com and outside U.S. borders is an alarming and potentially deadly trend, cautions the ...
Cached Medicine News:Health News:Coastal Healthcare Administrators Expands Provider Network to Santa Clara County 2Health News:More blood vessels in hormone-resistant prostate tumors 2Health News:Low cholesterol transfer protein activity associated with heart disease risk 2Health News:CIA Requests its Own Documents from Author 2Health News:CIA Requests its Own Documents from Author 3Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 2Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 3Health News:Physicians Coalition for Injectable Safety Warns Buttock-Boosting Injections Risky and Deadly 4
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: